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ABSTRACT
Background germline TP53 gene pathogenic variants 
(pv) cause a very high lifetime risk of developing cancer, 
almost 100% for women and 75% for men. in the UK, 
annual Mri breast screening is recommended for female 
TP53 pv carriers. The signiFY study (Magnetic resonance 
imaging screening in li Fraumeni syndrome: an exploratory 
whole body Mri) study reported outcomes of whole- body 
Mri (WB- Mri) in a cohort of 44 TP53 pv carriers and 44 
matched population controls. The results supported the use 
of a baseline WB- Mri screen in all adult TP53 pv carriers. 
here we report the acceptability of WB- Mri screening and 
effects on psychosocial functioning and health- related 
quality of life in the short and medium terms.
Methods Psychosocial and other assessments were 
carried out at study enrolment, immediately before 
Mri, before and after Mri results, and at 12, 26 and 52 
weeks’ follow- up.
Results WB- Mri was found to be acceptable with high 
levels of satisfaction and low levels of psychological 
morbidity throughout. although their mean levels of 
cancer worry were not high, carriers had significantly more 
cancer worry at most time- points than controls. They also 
reported significantly more clinically significant intrusive 
and avoidant thoughts about cancer than controls at all 
time- points. There were no clinically significant adverse 
psychosocial outcomes in either carriers with a history of 
cancer or in those requiring further investigations.
Conclusion WB- Mri screening can be implemented in 
TP53 pv carriers without adverse psychosocial outcomes 
in the short and medium terms. a previous cancer 
diagnosis may predict a better psychosocial outcome. 
some carriers seriously underestimate their risk of cancer. 
carriers of pv should have access to a clinician to help 
them develop adaptive strategies to cope with cancer- 
related concerns and respond to clinically significant 
depression and/or anxiety.
InTRoduCTIon
Li- Fraumeni syndrome (LFS) is a rare, dominantly 
inherited, highly penetrant cancer predisposition 
syndrome. The majority of families have a germ-
line pathogenic variant (pv) in the TP53 gene.1–4 
The cancers associated with LFS include breast 
cancer, sarcoma, adrenocortical carcinoma and brain 
tumours.3 4 Cancers are typically early onset (two to 
three decades before the median general population 
incidence) and there is also an increased risk of other 
cancers.5–7 The lifetime risk of cancer is very high for 
pv carriers when detected in a clinical context: almost 
100% for women and 75% for men.8 However, our 
understanding of penetrance and cancer patterns is 
incomplete, as evidence from genome- wide studies 
has identified pv in TP53 in individuals who do not 
meet the LFS testing criteria.8
In 2016, the American Association for Cancer 
Research held a meeting of international LFS 
experts to develop consensus cancer surveil-
lance recommendations. A combination of phys-
ical exams, blood tests and imaging based on the 
earlier ‘Toronto protocol’ was proposed.9 10 In 
the UK, current screening guidelines for TP53 
mutation carriers recommend annual MRI breast 
screening in women aged 20–49 and advise consid-
ering continuing this regimen past the age of 
50.11 12 Discussion of risk- reducing mastectomy is 
also recommended. Screening across UK genetics 
centres is variable, most offering a rapid review of 
symptoms in carriers.12
Internationally, there is increasing interest in the 
use of whole- body MRI (WB- MRI) as a screening 
tool,9–18 because, unlike other imaging approaches, 
ionising radiation, which may further increase cancer 
risk, is not used. In the UK, the SIGNIFY (Magnetic 
Resonance Imaging screening in Li Fraumeni 
syndrome: An exploratory whole body MRI) study 
recently reported the outcomes of WB- MRI in a 
cohort of 44 TP53 pv carriers and 44 matched popu-
lation controls.12 The results supported the use of a 
baseline WB- MRI screen as a minimum in all TP53 pv 
carriers in addition to the established breast screening 
programme.12 Further evidence supporting the use 
of a baseline WB- MRI screen for early detection of 
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treatable tumours comes from a meta- analysis of 13 cohorts with 
a total of 578 TP53 pv carriers.14 An annual WB- MRI screen for 
all TP53 pv carriers is being considered for adoption as a national 
guideline in the UK.18
Alongside clinical outcomes, it is important to evaluate possible 
psychosocial morbidity associated with screening. The psychoso-
cial impact of screening with WB- MRI in TP53 carriers is largely 
unknown. An Australian group evaluated the use of WB- MRI 
in a cohort of 17 TP53 carriers. They found that participants 
were not overburdened and they experienced mainly positive 
psychological outcomes from participation.17 However, this 
study reports only preliminary results from a small cohort and 
larger longitudinal studies are required.
A German group evaluated the psychosocial impact of WB- MRI 
in a healthy general population cohort. They found that partici-
pants overestimated the personal benefit of undergoing WB- MRI 
and experienced no long- term effects on health- related quality of 
life (HRQoL) or depressive symptoms.19 However, those requiring 
further investigations for incidental findings experienced moderate 
or severe psychological distress.20
The UK MARIBS study (study of magnetic resonance imaging 
(MRI) for breast screening) evaluated annual breast MRI and 
mammography screening in BRCA1/2 pv carriers at a signifi-
cantly high risk for breast cancer.21 22 Both imaging techniques 
were acceptable; psychological morbidity was low, and women 
were significantly less anxious and depressed after screening than 
they had been at baseline. However, MRI caused greater distress 
than mammograms, and this MRI- related distress was found to 
persist at 6 weeks’ follow- up. The psychosocial impact of annual 
WB- MRI in TP53 carriers requires further investigation.
Here we report the short- term and medium- term psychosocial 
effects, HRQoL and acceptability of WB- MRI scanning carried 
out as part of the SIGNIFY study.
MeThodS
Study subjects and procedures
The SIGNIFY study compared the incidence of malignancies 
diagnosed in asymptomatic TP53 pv carriers using WB- MRI 
screening with that in general population controls. It also 
assessed the incidence of non- malignant disease, the investi-
gations required to determine the relevance of non- malignant 
disease, and the psychosocial impact and acceptability of 
WB- MRI screening. Full details of design, methods and results 
have been reported previously.12
Participants were recruited between November 2012 and July 
2016 and consisted of two cohorts: TP53 pv carriers, and age- 
matched (±5 years) and sex- matched population controls.
TP53 pv carriers were identified and recruited consecutively 
through clinical genetics services in the UK and Ireland and 
referred to either the Royal Marsden NHS Foundation Trust 
(RMH) or the Central Manchester University Hospitals NHS 
Foundation Trust. Inclusion criteria were carriers of a germ-
line TP53 pv (not known to be low penetrance or a variant of 
unknown significance in the opinion of a geneticist) and aged 
between 18 and 60 years. Carriers with a malignancy diagnosed 
in the previous 5 years (except for non- melanomatous skin 
cancer or cervical carcinoma in situ) were excluded. Population 
controls were recruited in London through local advertisements 
and seen at the RMH. Inclusion criteria for controls were no 
personal history of cancer, no current symptoms suggestive of 
cancer and a minimal family history of cancer (no first- degree 
relative diagnosed <50 years, and at most only one first- degree, 
second- degree or third- degree relative diagnosed at any age).
All participants were invited to take part in this concurrent 
psychosocial study. The psychosocial impact was assessed using 
a set of standardised questionnaires adapted from those used 
in the MARIBS study.22 The questionnaires measured anxiety 
and depression, cancer worry, physical and psychological 
health, perceived risk of cancer, satisfaction with the process 
of screening, and the presence of intrusive thoughts relating 
to MRI screening and cancer anxiety. Those participants with 
a previous cancer diagnosis but meeting the eligibility criteria 
were asked to answer in respect to their cancer worries relating 
to a future diagnosis.
Questionnaire booklets were administered at seven time- 
points: (1) study enrolment (baseline), (2) on arrival at the MRI 
appointment, (3) pre- MRI and (4) post- MRI results, and (5) 12, 
(6) 26 and (7) 52 weeks post results. Questionnaires 1–4 were 
administered for all patients entered into the study. Question-
naires 5–7 were administered only for patients not diagnosed 
with cancer during the course of the study, as a result of the 
WB- MRI. Those diagnosed with cancer during the course of 
the study were invited to complete the questionnaires, as appro-
priate, up to the time of diagnosis. Each questionnaire booklet 
took a maximum of 20 min to complete.
Study measures
The Hospital Anxiety and Depression Scale (HADS) is a 14- item 
scale with two subscales of seven items measuring the presence 
and severity of anxiety and depression.23 Scores >11 suggest 
clinically significant anxiety or depression.
The Cancer Worry Scale Revised is an eight- item scale that 
measures worry about the risk of developing cancer.24–27 A 
higher score indicates greater worry.
The Impact of Events Scale (IES) is a 15- item scale measuring the 
frequency of intrusive and avoidant thoughts about a specific life 
event.28 Respondents completed one scale for cancer and another 
for MRI. A higher score indicates higher distress levels; a score 
of >8.5 on either scale indicates clinically significant levels of 
distress.29
The Spielberger State Anxiety Inventory- B (brief form) is a six- 
item scale abbreviated from the original 20- item scale30 and evalu-
ates situational factors that may influence anxiety levels.31 32 In this 
study it was used to measure state anxiety related to the MRI scan.
The Health Questionnaire (HQ) is a seven- item scale which 
was developed for use in a study investigating distress caused by 
attending routine breast screening.33 Respondents indicate for 
each stress- sensitive behaviour whether, in the last week, it has 
been ‘better than normal’ (score 0), same as normal (score 1) or 
worse than normal (score 2).
The Short Form-36 Health Survey V.2 (SF36- II) is a 36- item 
generic measure of HRQoL34 35 measuring eight dimensions of 
health. Scores are converted linearly to a 0–100 scale, with a 
higher score representing better functioning. Summary scores 
are calculated for physical health and mental health.
In Perceived Risk, participants rate their perceived risk of 
developing cancer compared with the average person’s risk and 
express their lifetime risk of developing cancer as a percentage.
Screening Satisfaction Questionnaire (SSQ) is a series of Likert 
scales originally designed to assess the satisfaction of individuals 
undergoing breast mammography36 and later adapted for MRI 
screening.22 The higher the score, the lower the satisfaction.
In the Acceptability of Screening, participants were asked ‘If 
you were offered an MRI scan next year, would you attend?’ and 
‘would you encourage a family member to attend for an MRI 
screening scan?’
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Table 1 Sociodemographic characteristics of cohorts
Carriers 
(n=44)
Controls 
(n=44)
Sex χ2=0.00, p=1.00
  Female 27 (61%) 27 (61%)
  Male 17 (39%) 17 (39%)
Age t=−0.33, p=0.75
  Mean 37.6 38.3
  Range 19–58 22–59
Ethnicity χ2=1.38, p=0.71
  White 42 (95%) 40 (91%)
  Asian/Asian British 1 (2%) 2 (5%)
  Chinese/Other 0 1 (2%)
  Mixed 1 (2%) 1 (2%)
Education χ2=21.39, p=<0.005*
  None 2 (5%) 0
  School to 16 9 (20%) 3 (7%)
  School to 18 9 (20%) 1 (2%)
  Technical 10 (23%) 5 (11%)
  Degree/postgraduate 14 (32%)* 34 (77%)*
  Missing 0 1 (2%)
Employment χ2=2.05, p=0.56
  Currently employed 36 (82%) 38 (86%)
  Not currently employed 6 (14%) 3 (7%)
  Retired 2 (5%) 2 (5%)
  Missing 0 1 (2%)
Marital status χ2=0.72, p=0.70
  Married 15 (63%) 29 (66%)
  Single 9 (38%) 14 (32%)
  Divorced 0 1 (2%)
  Missing 20 0
Socioeconomic classification χ2=11.22, p=0.04*
  Professional/managerial 21 (48%)* 36 (82%)*
  Skilled manual/non- 
manual
15 (34%) 5 (11%)
  Partly skilled manual/
unskilled
8 (18%) 3 (7%)
  Missing 0 0
*Significant difference between carriers and controls.
Sample size and statistical analysis
SIGNIFY had 88 participants: 44 TP53 pv carriers and 44 
healthy population controls. This sample size was based on the 
expected cancer detection rates using WB- MRI screening in the 
two groups.12
If <75% of the items on any questionnaire were completed, 
the data were excluded. Where>75% of items were completed, 
a pro rata total score was calculated. The only exception was for 
the SF36- II, where data were excluded when <50% of the items 
of a subscale were completed, as recommended by the question-
naire developers.37
Descriptive statistics were calculated to summarise the charac-
teristics of participants and the questionnaire data. Between- group 
differences at the various time- points were analysed using the 
Mann- Whitney U test, Fisher’s exact probability test and the χ2 
test as appropriate; within- group changes over time were evalu-
ated using the Wilcoxon signed- rank test and the McNemar test.
The effects of other variables such as previous cancer diag-
nosis and undergoing additional investigations post- MRI were 
analysed using the Mann- Whitney U test and the χ2 test. Alpha 
was set at 0.05 (two- tailed).
Data were analysed using SPSS V.24.0.
ReSulTS
Sample characteristics and response rate
As previously reported, 6 of 44 (14%) carriers were diagnosed 
with cancer during their involvement in the study.12
All 88 (100%) participants completed the baseline question-
naires. Overall, over 52 weeks, questionnaire compliance was 
85.3% (510 of 598 questionnaires administered). No significant 
difference in questionnaire response rate was observed between 
carriers and controls (p=0.38). Non- response was not associ-
ated with an adverse or clinically significant baseline score on 
a psychological scale (HADS, p=0.28; IES, p=0.12) or with a 
previous cancer diagnosis (p=0.65).
The sociodemographic characteristics of participants are 
shown in table 1. There were 27 women and 17 men in each 
cohort. The mean ages of carriers and controls were 37.6 years 
and 38.3 years, respectively. Most participants were white (95% 
carriers, 91% controls), in professional or managerial positions 
(50% carriers, 82% controls), and married (63% carriers, 66% 
controls). The number of people in professional jobs was higher 
in controls (χ2=0.36, p=0.02), and the control group had more 
people with degrees and postgraduate qualifications (χ2=0.43, 
p=0.005).
hospital Anxiety and depression Scale
The prevalence of clinically significant anxiety and depression 
(score ≥10) did not differ significantly between the groups 
at any time- point. Similarly, the mean scores of carriers and 
controls were similar throughout the study. At 12 weeks post-
results, carriers reported more borderline and clinically signifi-
cant anxiety combined (score ≥8) than controls (p=0.036). The 
anxiety scores of carriers declined significantly from baseline to 
preresults (Z=−2.07, p=0.04; table 2).
In carriers, the prevalence of clinically significant or border-
line anxiety and depression in those with a history of cancer did 
not differ at any time- point from those without such a history 
(table 3). Similarly, these two groups did not differ for anxiety 
and depression scores (table 3).
The prevalence of clinically significant or borderline anxiety 
and depression did not differ significantly at any time- point for 
carriers requiring further investigations compared with those 
who did not (table 4).
Cancer Worry Scale Revised
Carriers had significantly greater mean cancer worry scores 
than controls at baseline (U=499, <p=0.0005), at 26 weeks’ 
follow- up (U=289, <p=0.0005) and at 52 weeks’ follow- up 
(U=219, <p=0.0005). No significant changes over time were 
observed in carriers. In contrast, the mean cancer worry scores 
declined significantly in controls between baseline and 52 weeks’ 
follow- up (Z=−2.06, p=0.04) (table 2).
Having a previous cancer diagnosis and having further inves-
tigations did not have a significant effect, at any time- point, in 
carriers.
IeS: thoughts about cancer
Intrusive thoughts about cancer
Compared with controls, carriers had more frequent intrusive 
thoughts at every time- point (preresults U=264, p=<0.0005; 
12 weeks’ follow- up U=263, p=<0.0005; 26 weeks’ follow- up 
U=198, p=<0.0005; and 52 weeks’ follow- up U=192, 
 o
n
 N
ovem
ber 12, 2019 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106407 on 12 November 2019. Downloaded from 
4 Bancroft EK, et al. J Med Genet 2019;0:1–11. doi:10.1136/jmedgenet-2019-106407
Cancer genetics
Ta
bl
e 
2 
De
sc
rip
tiv
e 
st
at
is
tic
s 
an
d 
su
m
m
ar
y 
of
 p
sy
ch
ol
og
ic
al
 o
ut
co
m
es
Sc
al
e
Sc
al
e 
ra
ng
e/
th
re
sh
ol
d
St
ud
y 
en
ro
lm
en
t
A
t 
M
RI
 a
pp
oi
nt
m
en
t
Pr
er
es
ul
ts
12
 w
ee
ks
 a
ft
er
 r
es
ul
ts
26
 w
ee
ks
 a
ft
er
 r
es
ul
ts
52
 w
ee
ks
 a
ft
er
 r
es
ul
ts
Ca
rr
ie
rs
 
(n
=
44
)
Co
nt
ro
ls
 
(n
=
44
)
Ca
rr
ie
rs
 
(n
=
37
)
Co
nt
ro
ls
 
(n
=
37
)
Ca
rr
ie
rs
 
(n
=
36
)
Co
nt
ro
ls
 
(n
=
38
)
Ca
rr
ie
rs
 (n
=
29
)
Co
nt
ro
ls
 
(n
=
38
)
Ca
rr
ie
rs
 (n
=
33
)
Co
nt
ro
ls
 
(n
=
38
)
Ca
rr
ie
rs
 (n
=
28
)
Co
nt
ro
ls
 
(n
=
34
)
HA
DS
 A
nx
ie
ty
,
m
ea
n 
(S
D)
; n
 a
bo
ve
 
th
re
sh
ol
d
0–
1
6.
2 
(3
.9
)*
4.
9 
(3
.3
)
–
–
5.
3 
(3
.9
)*
4.
6 
(3
.3
)
5.
8 
(4
.3
)
4.
1 
(3
.1
)
5.
9 
(4
.1
)
4.
4 
(2
.9
)
5.
7 
(4
.8
)
4.
1 
(3
.2
)
0–
7
28
36
29
28
19
34
22
32
19
30
8–
10
10
5
3
9
5†
1†
7
5
5
2
>
10
6
3
4
1
5†
3†
2
1
4
2
HA
DS
 D
ep
re
ss
io
n,
m
ea
n 
(S
D)
; n
 a
bo
ve
 
th
re
sh
ol
d
0–
21
2.
3 
(2
.5
)
2.
1 
(1
.9
)
–
–
2.
4 
(2
.8
)
2.
3 
(2
.6
)
2.
3 
(3
.3
)
1.
8 
(2
.3
)
2.
6 
(2
.8
)
2.
3 
(2
.8
)
3.
0 
(3
.8
)
2.
1 
(2
.3
)
0–
7
42
43
34
36
26
37
27
37
25
33
8–
10
2
1
0
1
1
1
4
0
2
1
>
10
0
0
2
1
2
0
0
1
1
0
CW
S-
 R,
 m
ea
n 
(S
D)
8–
32
14
.4
 (3
.6
)†
12
.2
 (1
.7
)*
†
–
–
–
–
13
.6
 (4
.4
)
12
.1
 (1
.9
)
14
.7
 (4
.2
)†
11
.9
 (1
.8
)†
14
.5
 (4
.3
)†
11
.9
 (1
.4
)*
†
IE
S:
 c
an
ce
r
in
tr
us
io
n
0–
35
–
–
–
–
11
.4
 (9
.1
)*
†
3.
0 
(4
.9
)†
*
8.
3 
(9
.1
)*
†
1.
8 
(3
.1
)†
11
.0
 (1
0.
0)
†
1.
7 
(3
.5
)*
†
9.
2 
(8
.2
)†
2.
1 
(3
.8
)†
0–
8
15
33
18
35
15
36
14
32
>
8
21
†
5†
10
†
3†
16
†
2†
13
†
2†
IE
S:
 c
an
ce
r a
vo
id
an
ce
0–
40
–
–
–
–
13
.3
 (1
0.
5)
†
7.
0 
(8
.2
)*
†
9.
9 
(9
.0
) †
3.
8 
(5
.9
)*
†
13
.4
 (1
1.
7)
†
4.
3 
(6
.7
)†
10
.1
 (9
.4
)†
2.
6 
(4
.6
)*
†
0–
8
13
24
12
31
12
31
12
30
>
8
23
†
14
†*
16
†
7*
†
19
†
7†
15
†
4†
*
IE
S:
 M
RI
0–
35
–
–
–
–
–
–
1.
7 
(3
.6
)
0.
5 
(1
.8
)
3.
1 
(8
.8
)†
0.
3 
(1
.4
)†
1.
2 
(3
.2
)†
0.
1 
(0
.3
)†
0–
8
26
37
29
38
26
34
>
8
2
1
2
0
1
0
IE
S:
 M
RI
 a
vo
id
an
ce
0–
40
–
–
–
–
–
–
2.
8 
(5
.5
)
2.
8 
(1
.8
)
4.
1 
(9
.3
)†
0.
8 
(1
.4
)†
1.
8 
(3
.4
)
1.
0 
(0
.3
)
0–
8
24
35
29
35
26
31
>
8
4
3
2
3
1
3
SS
AI
, m
ea
n 
(S
D)
6–
24
–
–
7.
2 
(3
.3
)
7.
3 
(3
.2
)
–
–
–
–
–
–
–
–
He
al
th
 Q
ue
st
io
nn
ai
re
, 
m
ea
n 
(S
D)
0–
14
7.
0 
(2
.6
)
6.
8 
(2
.2
)
–
–
8.
1 
(2
.8
)†
6.
9 
(2
.2
)†
7.
1 
(2
.5
)
7.
7 
(2
.1
)
7.
2 
(2
.4
)
7.
2 
(2
.2
)
7.
2 
(2
.6
)
7.
6 
(1
.5
)
SF
36
- II
 p
hy
si
ca
l 
co
m
po
ne
nt
 s
um
m
ar
y,
 
m
ea
n 
(S
D)
0–
10
0
49
.2
 (6
.1
)†
52
.1
 (4
.5
)†
–
–
–
–
50
.7
 (8
.5
)
52
.0
 (5
.5
)
48
.4
 (8
.2
)†
51
.7
 (9
.0
)†
47
.9
 (9
.8
)†
51
.7
 (7
.3
)†
SF
36
- II
 m
en
ta
l 
co
m
po
ne
nt
 s
um
m
ar
y,
 
m
ea
n 
(S
D)
0–
10
0
50
.2
 (8
.3
)†
54
.0
 (6
.8
)†
–
–
–
–
50
.0
 (1
0.
2)
53
.2
 (9
.9
)
49
.3
 (1
0.
0)
52
.1
 (9
.5
)
49
.3
 (1
0.
0)
53
.3
 (8
.7
)
Ri
sk
 P
er
ce
pt
io
n,
 m
ea
n 
(S
D)
0–
10
0
68
.7
† 
(2
4.
9)
27
.0
† 
(1
7.
8)
–
–
–
–
71
.2
† 
(2
4.
4)
30
.6
† 
(1
6.
4)
70
.6
† 
(2
5.
5)
33
.9
† 
(1
8.
7)
67
.7
† 
(2
7.
0)
35
.7
† 
(1
9.
4)
*S
ig
ni
fic
an
t d
iff
er
en
ce
 in
 s
co
re
s 
be
tw
ee
n 
tim
e-
 po
in
ts
 (s
am
e 
gr
ou
p)
 c
om
pa
re
d 
w
ith
 b
as
el
in
e 
(fi
rs
t) 
m
ea
su
re
.
†S
ig
ni
fic
an
t d
iff
er
en
ce
 in
 s
co
re
s 
be
tw
ee
n 
gr
ou
ps
.
CW
S-
 R,
 C
an
ce
r W
or
ry
 S
ca
le
 R
ev
is
ed
; H
AD
S,
 H
os
pi
ta
l A
nx
ie
ty
 a
nd
 D
ep
re
ss
io
n 
Sc
al
e;
 IE
S,
 Im
pa
ct
 o
f E
ve
nt
s 
Sc
al
e;
 S
F3
6-
 II,
 S
ho
rt
 F
or
m
-3
6 
He
al
th
 S
ur
ve
y 
V.
2;
 S
SA
I, 
Sp
ie
lb
er
ge
r S
ta
te
 A
nx
ie
ty
 In
ve
nt
or
y.
 o
n
 N
ovem
ber 12, 2019 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106407 on 12 November 2019. Downloaded from 
5Bancroft EK, et al. J Med Genet 2019;0:1–11. doi:10.1136/jmedgenet-2019-106407
Cancer genetics
Ta
bl
e 
3 
De
sc
rip
tiv
e 
st
at
is
tic
s 
an
d 
su
m
m
ar
y 
of
 p
sy
ch
ol
og
ic
al
 o
ut
co
m
es
 o
f T
P5
3 
ca
rr
ie
rs
 w
ith
 a
 p
re
vi
ou
s 
ca
nc
er
 d
ia
gn
os
is
 v
s 
w
ith
 th
os
e 
w
ho
 a
re
 u
na
ffe
ct
ed
Sc
al
e
Sc
al
e 
ra
ng
e/
th
re
sh
ol
d
St
ud
y 
en
ro
lm
en
t
Pr
er
es
ul
ts
12
 w
ee
ks
 a
ft
er
 r
es
ul
ts
26
 w
ee
ks
 a
ft
er
 r
es
ul
ts
52
 w
ee
ks
 a
ft
er
 r
es
ul
ts
Pr
ev
io
us
 
ca
nc
er
 (n
=
15
)
u
na
ff
ec
te
d 
(n
=
29
)
Pr
ev
io
us
 
ca
nc
er
 (n
=
14
)
u
na
ff
ec
te
d 
(n
=
22
)
Pr
ev
io
us
 
ca
nc
er
 (n
=
9)
u
na
ff
ec
te
d 
(n
=
20
)
Pr
ev
io
us
 c
an
ce
r 
(n
=
12
)
u
na
ff
ec
te
d 
(n
=
20
)
Pr
ev
io
us
 
ca
nc
er
 (n
=
9)
u
na
ff
ec
te
d 
(n
=
19
)
HA
DS
 A
nx
ie
ty
, m
ea
n 
(S
D)
; n
 
ab
ov
e 
th
re
sh
ol
d
0–
21
6.
3 
(3
.6
)
6.
1 
(4
.1
)
5.
3 
(3
.8
)
5.
3 
(4
.0
)
4.
9 
(4
.7
)
6.
3 
(4
.1
)
5.
6 
(3
.8
)
6.
1 
(4
.3
)
5.
7 
(3
.8
)
5.
7 
(5
.3
)
0–
7
10
19
11
18
6
13
8
14
7
12
8–
10
4
5
1
2
2
3
3
4
1
4
>
10
1
5
2
2
1
4
1
1
1
3
HA
DS
 D
ep
re
ss
io
n 
m
ea
n 
(S
D)
; 
n 
ab
ov
e 
th
re
sh
ol
d
0–
21
2.
1 
(2
.0
)
2.
4 
(2
.8
)
2.
3 
(2
.9
)
2.
5 
(2
.8
)
1.
7 
(2
.7
)
2.
6 
(3
.6
)
2.
8 
(3
.2
)
2.
4 
(2
.6
)
4.
1 
(3
.9
)
2.
5 
(3
.8
)
0–
7
15
27
13
21
8
18
10
18
7
18
8–
10
0
2
0
0
1
0
2
2
2
0
>
10
0
0
1
1
0
2
0
0
0
1
CW
S-
 R,
 m
ea
n 
(S
D)
8–
32
14
.2
 (2
.1
)
14
.5
 (4
.1
)
13
.1
 (2
.6
)
13
.8
 (5
.1
)
13
.4
 (2
.2
)
15
.4
 (4
.9
)
13
.0
 (2
.8
)
15
.2
 (4
.7
)
14
.2
 (2
.1
)
14
.5
 (4
.1
)
IE
S:
 c
an
ce
r
in
tr
us
io
n
0–
35
–
–
9.
6 
(6
.7
)
12
.6
 (1
0.
2)
*
8.
6 
(9
.0
)
8.
1 
(9
.4
)*
8.
2 
(8
.5
)
12
.6
 (1
0.
7)
8.
1 
(8
.4
)
9.
7 
(8
.3
)
0–
8
5
9
5
13
6
8
4
10
>
8
9
13
4
6
5
12
4
9
IE
S:
 c
an
ce
r a
vo
id
an
ce
0–
40
–
–
12
.5
 (8
.6
)
13
.8
 (1
1.
7)
9.
0 
(7
.8
)
10
.4
 (9
.7
)
11
.5
 (1
1.
6)
14
.4
 (1
0.
0)
7.
8 
(7
.2
)
11
.1
 (1
0.
2)
0–
8
5
7
3
8
6
6
3
8
>
8
9
15
6
11
5
14
5
11
*S
ig
ni
fic
an
t d
iff
er
en
ce
 in
 m
ea
n 
sc
or
es
 b
et
w
ee
n 
tim
e-
 po
in
ts
 (s
am
e 
gr
ou
p)
.
CW
S-
 R,
 C
an
ce
r W
or
ry
 S
ca
le
 R
ev
is
ed
; H
AD
S,
 H
os
pi
ta
l A
nx
ie
ty
 a
nd
 D
ep
re
ss
io
n 
Sc
al
e;
 IE
S,
 Im
pa
ct
 o
f E
ve
nt
s 
Sc
al
e.
 o
n
 N
ovem
ber 12, 2019 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106407 on 12 November 2019. Downloaded from 
6 Bancroft EK, et al. J Med Genet 2019;0:1–11. doi:10.1136/jmedgenet-2019-106407
Cancer genetics
Ta
bl
e 
4 
De
sc
rip
tiv
e 
st
at
is
tic
s 
an
d 
su
m
m
ar
y 
of
 p
sy
ch
ol
og
ic
al
 o
ut
co
m
es
 o
f T
P5
3 
ca
rr
ie
rs
 re
qu
iri
ng
 fu
rt
he
r i
nv
es
tig
at
io
ns
 v
s 
w
ith
 th
os
e 
no
t r
eq
ui
rin
g 
fu
rt
he
r i
nv
es
tig
at
io
ns
Sc
al
e
Sc
al
e 
ra
ng
e/
th
re
sh
ol
d
St
ud
y 
en
ro
lm
en
t
12
 w
ee
ks
 a
ft
er
 r
es
ul
ts
*
+
26
 w
ee
ks
 a
ft
er
 r
es
ul
ts
*
52
 w
ee
ks
 a
ft
er
 r
es
ul
ts
*
n
o 
in
ve
st
ig
at
io
ns
 
(n
=
28
)
Fu
rt
he
r 
in
ve
st
ig
at
io
ns
 
(n
=
16
)
n
o 
in
ve
st
ig
at
io
ns
 
(n
=
20
)
Fu
rt
he
r 
in
ve
st
ig
at
io
ns
 
(n
=
9)
n
o 
in
ve
st
ig
at
io
ns
 
(n
=
18
)
Fu
rt
he
r 
in
ve
st
ig
at
io
ns
 
(n
=
13
)
n
o 
in
ve
st
ig
at
io
ns
 
(n
=
18
)
Fu
rt
he
r 
in
ve
st
ig
at
io
ns
 
(n
=
10
)
HA
DS
 A
nx
ie
ty
, m
ea
n 
(S
D)
; n
 
ab
ov
e 
th
re
sh
ol
d
0–
21
6.
0 
(4
.4
)
6.
6 
(3
.1
)
5.
2 
(4
.5
)
7.
2 
(3
.5
)
5.
6 
(3
.4
)
6.
3 
(5
.0
)
5.
6 
(5
.0
)
5.
8 
(4
.8
)
0–
7
18
11
14
5
13
9
13
6
8–
10
5
4
3
2
4
3
2
3
>
10
5
1
3
2
1
1
3
1
HA
DS
 D
ep
re
ss
io
n 
m
ea
n 
(S
D)
; 
n 
ab
ov
e 
th
re
sh
ol
d
0–
21
1.
8 
(1
.9
)
3.
1 
(3
.1
)
1.
9 
(3
.1
)
3.
0 
(3
.8
)
2.
1 
(2
.4
)
3.
2 
(3
.2
)
2.
7 
(3
.0
)
3.
6 
(5
.1
)
0–
7
28
14
18
8
16
11
16
9
8–
10
0
0
1
0
2
2
2
0
>
10
0
2
1
1
0
0
0
1
CW
S-
 R,
 m
ea
n 
(S
D)
8–
32
13
.7
 (2
.1
)
15
.6
 (5
.1
)
13
.2
 (2
.4
)
14
.6
 (7
.1
)
14
.4
 (3
.6
)
15
.1
 (5
.3
)
14
.0
 (3
.4
)
15
.4
 (5
.7
)
IE
S:
 c
an
ce
r
in
tr
us
io
n
0–
35
–
–
8.
6 
(8
.4
)
7.
4 
(1
1.
0)
10
.3
 (9
.7
)
11
.9
 (1
0.
8)
8.
2 
(6
.6
)
10
.9
 (1
0.
6)
0–
8
11
7
9
6
9
5
>
8
8
2
9
7
8
5
IE
S:
 c
an
ce
r a
vo
id
an
ce
0–
40
–
–
9.
1 
(7
.9
)
11
.6
 (1
1.
4)
11
.0
 (1
1.
6)
16
.6
 (1
1.
6)
8.
2 
(7
.6
)
13
.3
 (1
1.
6)
0–
8
8
4
9
3
9
3
>
8
11
5
9
10
8
7
*n
=
nu
m
be
r o
f q
ue
st
io
nn
ai
re
s 
re
tu
rn
ed
 a
t e
ac
h 
tim
e-
 po
in
t. 
Pa
rt
ic
ip
an
ts
 re
ce
iv
in
g 
a 
ca
nc
er
 d
ia
gn
os
is
 d
id
 n
ot
 c
om
pl
et
e 
qu
es
tio
nn
ai
re
s 
be
yo
nd
 th
e 
tim
e 
of
 d
ia
gn
os
is.
CW
S-
 R,
 C
an
ce
r W
or
ry
 S
ca
le
 R
ev
is
ed
; H
AD
S,
 H
os
pi
ta
l A
nx
ie
ty
 a
nd
 D
ep
re
ss
io
n 
Sc
al
e;
 IE
S,
 Im
pa
ct
 o
f E
ve
nt
s 
Sc
al
e.
 o
n
 N
ovem
ber 12, 2019 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106407 on 12 November 2019. Downloaded from 
7Bancroft EK, et al. J Med Genet 2019;0:1–11. doi:10.1136/jmedgenet-2019-106407
Cancer genetics
Table 5 Participants’ classification of their risk of cancer when compared with the general population risk
Baseline 12 weeks after results 26 weeks after results 52 weeks after results
Carriers (n=44) Controls (n=42) Carriers (n=28) Controls (n=38) Carriers (n=31) Controls (n=39) Carriers (n=26) Controls (n=33)
Lower 0 11 (26%) 0 7 (18%) 0 10 (26%) 0 6 (18%)
The same 0 28 (67%) 1 (4%) 27 (71%) 1 (3%) 25 (64%) 2 (8%) 21 (64%)
Slightly increased 7 (16%) 3 (7%) 3 (11%) 3 (8%) 6 (19%) 4 (10%) 5 (19%) 5 (15%)
Moderately increased 13 (30%) 0 9 (32%) 1 (3%) 6 (19%) 0 4 (15%) 1 (3%)
Strongly increased 24 (55%) 0 15 (54%) 0 18 (58%) 0 15 (58%) 0
p=<0.0005). They also reported significantly more clinically 
significant intrusive thoughts (score >9) than controls at all 
time- points: at preresults (p<0.0005), at 12 weeks’ follow- up 
(p=0.01), at 26 weeks’ follow- up (p=<0.0005) and at 52 
weeks’ follow- up (p=<0.0005; table 2).
Intrusion scores declined significantly in carriers between 
preresults and 12 weeks’ follow- up (Z=−2.15, p=0.032). 
Scores also declined in controls between preresults and 26 
weeks’ follow- up (Z=−2.68, p=0.07).
For carriers without a previous cancer diagnosis (table 3), 
intrusion scores fell between preresults and 12 weeks’ follow- up 
(12.6 vs 8.1; Z=−2.63, p=0.009).
No significant differences in intrusion scores were found 
at any time- point for carriers requiring further investigations 
compared with those who did not (table 4).
Avoidance of thoughts about cancer
Carriers reported significantly more clinically significant avoid-
ance than controls at all time- points: preresults (p=0.036), 12 
weeks’ follow- up (p=0.002), 26 weeks’ follow- up (p=0.01) and 
52 weeks’ follow- up (p=<0.0005).
Compared with controls, carriers had more frequent avoid-
ance at every time- point (preresults U=423, p=0.005; 12 weeks’ 
follow- up U=304, p=0.002; 26 weeks’ follow- up U=296, 
p=<0.0005; and 52 weeks’ follow- up U=252, p=0.01).
In the control group, compared with preresults, the prevalence 
of clinically significant avoidance fell at 12 weeks’ follow- up 
(McNemar: p=0.04) and at 52 weeks’ follow- up (McNemar: 
p=0.01).
Avoidance scores in controls declined significantly between 
preresults and 12 weeks’ follow- up (Z=−2.73, p=0.006) and 
preresults and 52 weeks’ follow- up (Z=−3.38, p=0.001).
No significant differences in avoidance scores were found 
at any time- point for carriers requiring further investigations 
compared with those who did not.
IeS: thoughts about MRI
Intrusion of thoughts about MRI
The intrusion scores of carriers were significantly higher than 
those of controls at 26 weeks (U=330, p=0.05) and 52 weeks 
(U=284, p=0.02) postresults.
There were no significant differences in the number of partic-
ipants over the threshold of clinically significant levels of intru-
sive thoughts about MRI between carriers and controls, or 
within each group, at any time- point (table 2).
Intrusion scores declined significantly in controls between 12 
and 52 weeks postresults (Z=−2.12, p=0.03). However, all 
mean scores were very low and overall represented low levels of 
avoidant thoughts about the MRI scan.
Mean intrusion scores did not vary significantly across time- 
points for mutation carriers.
Avoidance of thoughts about MRI
There were no significant differences in clinically significant 
avoidance between carriers or controls, or within each group, at 
any time- point (table 2). The mean avoidance score of carriers 
was significantly higher than that of controls 26 weeks post-
results (U=301, p=0.05). Mean avoidance scores did not vary 
significantly over time within carrier or control groups. All mean 
scores were very low.
Spielberger State Anxiety Inventory
No significant difference at the time of MRI was detected in 
state anxiety between carriers and controls and the mean scores 
were overall low on the scale.
health Questionnaire
Carriers had significantly higher mean scores for stress- sensitive 
behaviours preresults compared with controls at 12 weeks 
(U=472, p=0.02) but not at other time- points. Scores did not 
vary significantly over time within either group.
SF36-II questionnaire
Physical function
Carriers had poorer physical functioning than controls at base-
line and at 26 and 52 weeks postresults (U=645, p=0.007; 
U=398, p=0.02; U=318, p=0.03, respectively). However, the 
effect size was small and the mean values were close to the stan-
dardised mean of 50 across both groups and at all time- points.
No significant differences in mean scores were detected for 
physical functioning scores between baseline and any other time- 
point in either carriers or controls.
Mental function
Carriers had poorer mental functioning than controls at baseline 
(U=723, p=0.03). However, the effect size was small and the 
mean values were close to the standardised mean of 50 across 
both groups and at all time- points.
No significant differences in mean scores were detected for 
mental functioning scores between baseline and any other time- 
point in either carriers or controls.
Risk Perceptions
Carriers estimated their risk of developing cancer as higher than 
controls at every time- point (baseline U=183, p=<0.0005; 12 
weeks U=116, p=<0.0005; 26 weeks U=165, p=<0.0005; 52 
weeks U=147, p=<0.0005) (table 2).
The majority of carriers classified their risk as ‘moderately or 
strongly increased’ (table 5) when compared with the general 
population risk, with 54%–58% correctly perceiving their risk 
as strongly increased. Of the controls, 64%–73% perceived their 
risk to be ‘the same’ as the general population.
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Table 6 Participants’ mean screening satisfaction scores
Convenience and 
access
Staff interpersonal 
skills Information transfer Physical surroundings*
Perceived technical 
competence General satisfaction
Carrier 
(n=37)
Control 
(n=37)
Carrier 
(n=37)
Control 
(n=37)
Carrier 
(n=37)
Control 
(n=37)
Carrier 
(n=37)
Control 
(n=37)
Carrier 
(n=37)
Control 
(n=37)
Carrier 
(n=37)
Control 
(n=37)
Mean (SD) 7.5 (2.8) 6.9 (2.3) 4.5 (1.5) 5.0 (1.5) 6.2 (2.3) 6.3 (2.0) 8.4 (3.0) 10.8 (3.5) 4.8 (1.6) 5.2 (1.4) 6.8 (2.7) 7.3 (2.3)
Possible 
range
4–20 4–20 4–20 5–25 4–20 5–25
*Significant difference in mean scores between groups.
Screening Satisfaction
Carriers reported higher satisfaction scores with the physical 
surroundings of the MRI environment than controls (U=316, 
p=0.03; table 6).
Acceptability of Screening
Ninety- eight per cent of carriers and 77% of controls agreed 
that they would attend an offered MRI scan the following year 
at every time- point (12, 26 and 52 weeks postresults; p=0.015).
Eighty- six per cent of carriers and 86% of controls reported 
that they would encourage a family member to attend for MRI 
screening at every time- point.
dISCuSSIon
This is the first study to evaluate the psychosocial impact of 
WB- MRI in a cohort of TP53 pv carriers compared with a 
matched general population control group. Overall there were 
minimal adverse psychological outcomes among study partici-
pants; while carriers reported higher levels of cancer worry 
and depression, this was not negatively impacted by the use of 
WB- MRI screening.
Reassuringly, there were no statistically significant differences 
in the prevalence of clinically significant anxiety or depression 
between carriers and controls at any time- point (when using a 
HADS of >10). When a more stringent cut- off of 8 or more was 
used, the only difference between groups was at 12 weeks post-
results, when carriers reported more borderline and clinically 
significant anxiety (34%) than controls (11%). When compared 
with normative data for the HADS score from a study of a large 
sample of general practice registrants in North West England,38 
the prevalence of clinically significant anxiety and depression in 
carriers was not high. The HADS mean scores in carriers are also 
similar to those of other genetically high- risk populations.39 40
McBride et al17 reported anxiety scores in their cohort of LFS 
pv carriers to be highest at baseline, with a significant reduction 
2 weeks post- MRI. Similarly, we found that the highest values 
in both cohorts were recorded at baseline for anxiety on the 
HADS and IES scales. McBride et al17 suggest this could indicate 
a temporary increase in anxiety related to the anticipation of the 
MRI. Some of the difference may be related to anxiety about 
what the MRI might find: in the current study, there were no 
significant differences between groups when measuring MRI- 
specific anxiety. Falls in other measures over time support the 
concept that distress reduces after results are available. Twelve 
weeks after receipt of MRI results, IES values assessing intru-
sive thoughts about cancer were significantly lower in carriers 
compared with preresults. A significant reduction in IES scores 
was seen at 26 weeks in controls. Scores of ≥8 (representing 
clinically significant levels of avoidant thoughts about cancer) 
also became fewer with time in controls at 12 weeks after the 
MRI results. The hypothesis regarding concern about MRI find-
ings is supported by our finding of higher levels of stress- related 
behaviours (measured on the HQ) in carriers compared with 
controls immediately before the MRI results. This is further 
supported by the results of the MARIBS study, which reported 
high levels of baseline psychological morbidity that reduced 
post- MRI breast screening.22
A small proportion of participants (cases and controls) had 
ongoing distress after results were provided. At 12 weeks post-
results, 7% of carriers (3% of controls) had clinically significant 
levels of intrusive thoughts about the MRI, and 14% of carriers 
(8% of controls) had clinically significant levels of avoidant 
thoughts. There were no significant changes in the numbers of 
individuals affected by week 52, as numbers were small. In the 
general population, psychological reactions to MRI vary and 
a significant number of people have anxiety reactions ranging 
from anticipatory anxiety to a full- blown panic attack. Interven-
tions to minimise and predict such symptoms have been docu-
mented.41 Although 98% of carriers indicated that they would 
return for a further scan the following year, we recommend that 
the minority of carriers who suffer from significant MRI- related 
distress (be it pre- MRI, during MRI or post- MRI scan) should be 
offered evidence- based help in coping with future MRIs.
As expected, mean cancer- related worry scores were high in 
carriers and significantly higher than in controls. It is well docu-
mented that living with a TP53 pv is a psychosocial burden for 
patients.17 27 42 It is also known that living in a family with a TP53 
pv has an adverse psychosocial impact regardless of pv status.27 
It was also, therefore, a strength of this study that controls were 
sought outside of these families.
It could be hypothesised that carriers with a previous cancer 
diagnosis may have a worse psychosocial experience when 
undergoing cancer screening. However, a previous cancer diag-
nosis was not associated with any worse psychosocial outcomes. 
Indeed, carriers with a previous cancer had lower mean scores 
for anxiety at 6 and 12 months post- WB- MRI compared with 
unaffected carriers. This needs further exploration in a larger 
series, but may suggest a degree of post- traumatic growth among 
the participants with previous cancer diagnoses.43 This is a 
growing area of interest in cancer survivors.
Sensitive measures and interventions to manage fear of 
cancer recurrence are being evaluated.44 45 High levels of fear of 
recurrence are usually associated with psychological morbidity 
and poor HRQoL, as seen in carriers living at risk of multiple 
cancers.45 Therefore strategies to increase resilience and reduce 
cancer fear could be potentially very beneficial to improve 
psychosocial well- being in this group.
Importantly, no clinically significant differences were detected 
between carriers requiring additional investigations for an abnor-
mality found on MRI and those requiring no additional investi-
gations, either in the short or medium term. In McBride et al’s 
study, qualitative interviews found that, despite an initial high 
level of faith in the efficacy of WB- MRI, a large proportion of 
participants reported the MRI to be burdensome, particularly in 
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those requiring additional investigations.17 However, this study 
was limited by its small numbers (nine participants were inter-
viewed 6 months after the MRI and data collection is ongoing). 
We found no evidence to support this finding, with no differ-
ences reported in either HRQoL or psychosocial measures at 12, 
26 or 52 weeks post initial results. It is reasonable to assume 
that by 12 weeks any further investigations would have been 
completed and participants would have known the outcome. 
Therefore any short- term impact on distress levels during the 
period of uncertainty of a diagnosis may have been missed with 
this study design. Overall, our data indicate that additional 
investigations triggered by the MRI did not add a longer- term 
psychosocial burden for carriers.
In terms of general HRQoL, significant differences were 
detected in SF36 scores between carriers and controls in both 
physical and mental functioning. However, this did not change 
over time, and all scores were similar to previously published 
norms.34 Carriers had a slightly poorer overall HRQoL, but 
undergoing MRI screening had no impact on HRQoL.
Only 55%–57% of carriers correctly estimated their risk of 
cancer at each time- point as ‘strongly’ increased when compared 
with the general population risk. Almost half of pv carriers 
underestimated their lifetime risk of cancer, 15%–20% very 
substantially. This may be a coping strategy rather than a short-
coming regarding information given or understood. Either way, 
it highlights the need for ongoing easy- to- access information 
and support. McBride et al17 found that undergoing screening 
and having contact with a clinician were emotionally helpful.17 
Therefore, in addition to the utility of WB- MRI, future research 
should evaluate types of support for carriers undergoing 
screening.
The SSQ findings demonstrate very high satisfaction levels 
with all aspects of screening in all participants. Schmidt et 
al’s19 evaluation of WB- MRI screening in the general popula-
tion found similar results. Almost all carriers (98%) stated that 
they would attend for a repeat scan in a year’s time, demon-
strating a very high level of acceptability of WB- MRI screening. 
Significantly fewer controls (77%) stated they would attend for a 
repeat scan, perhaps because their risk of cancer was significantly 
lower. In both groups, 86% would recommend a relative attends 
for WB- MRI screening.
Strengths and limitations
Compliance with questionnaire completion was very good, 
and there was no association between an adverse baseline score 
and subsequent non- response. Of note, just three participants 
completed only the baseline questionnaire.
A unique strength of this study was the use of a control group. 
This, together with the longitudinal design, allowed compari-
sons between and within cohorts over time.
The two groups were well matched for a range of sociode-
mographic variables, including employment, marital status, 
ethnicity and age. However, controls had a significantly higher 
level of education and higher socioeconomic status than the 
carriers. Given that higher educational attainment and socioeco-
nomic status have been shown to protect against both depression 
and anxiety, the comparability of the two groups in terms of 
observed anxiety and depression is additionally reassuring.46
ConCluSIon
WB- MRI screening is very acceptable to carriers and is associ-
ated with minimal medium- term adverse psychosocial outcomes. 
The presence of a TP53 pv is well known to cause adverse 
psychosocial outcomes for some, but there is no evidence that 
WB- MRI screening exacerbated cancer worry or depression. 
There was evidence of a transient increase in anxiety pre- MRI, 
but this might have been due to anticipation of what screening 
might detect, rather than undergoing MRI. The study popula-
tion had a high level of satisfaction with the WB- MRI screening 
process.
Reassuringly there was no adverse psychosocial impact 
observed in the carriers requiring additional investigations for 
an abnormality detected at MRI, and a previous cancer diagnosis 
may predict a better psychosocial outcome.
Some carriers seriously underestimate their risk of cancer, 
raising the question of maladaptive coping strategies. We recom-
mend easy access to a clinician for all mutation carriers to help 
them cope with cancer- related concerns, including intrusive 
cancer- related thoughts and images, and to respond appropri-
ately to clinically significant depression and/or anxiety should it 
occur. Any carriers who suffer from procedural anxiety related 
to screening should be offered help from a clinician conversant 
with evidence- based anxiety management techniques.
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